Dan O'Day, Gilead CEO (Georgios Kefalas/EPA-EFE/Shutterstock)
December 15, 2020 05:08 PM ESTUpdated December 16, 02:18 AM
Deals
FDA+

Gilead’s Dan O’Day pulls the plug on the li­on’s share of their fil­go­tinib col­lab­o­ra­tion as the FDA erects a high safe­ty bar­ri­er. What went wrong?

John Carroll

Editor & Founder

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Ex­its con­tin­ue at FDA, as more staff in drug of­fice fol­low fired col­leagues out the door

Up­dat­ed: No­var­tis to buy Reg­u­lus Ther­a­peu­tics for up to $1.7B

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

FDA ap­proves J&J's rare dis­ease drug that's ex­pect­ed to com­pete with ar­genx and UCB

The End­points Slack in­ter­view: Arc In­sti­tute's Patrick Hsu on in­vest­ing, AI and new ways of re­search

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times